

# Johanne Silvain

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3305986/johanne-silvain-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

6,976  
citations

36  
h-index

82  
g-index

149  
ext. papers

8,373  
ext. citations

8.6  
avg, IF

5.17  
L-index

#	Paper	IF	Citations
122	Appropriate criteria for the definition of Type 4a MI. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	1
121	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 324-333	6.4	9
120	Clinical manifestations and outcomes of coronavirus disease-19 in heart transplant recipients: a multicentre case series with a systematic review and meta-analysis. <i>Transplant International</i> , <b>2021</b> , 34, 721-731	3	4
119	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , <b>2021</b> , 42, 2630-2642	9.5	13
118	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. <i>American Journal of Cardiovascular Drugs</i> , <b>2021</b> , 21, 681-691	4	0
117	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 297-308	59.2	41
116	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 225-235	6.4	17
115	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , <b>2021</b> , 159, 1415-1425	5.3	1
114	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. <i>European Heart Journal</i> , <b>2021</b> , 42, 323-334	9.5	21
113	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , <b>2021</b> , 159, 657-662	5.3	51
112	Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 143-150	3.3	2
111	Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 552-560	27.4	33
110	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. <i>American Heart Journal</i> , <b>2020</b> , 225, 27-37	4.9	4
109	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
108	Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. <i>American Heart Journal</i> , <b>2020</b> , 225, 60-68	4.9	6
107	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1676-1685	15.1	60
106	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 65-74	7	7

105	Quantitative flow ratio virtual stenting and post stenting correlations to post stenting fractional flow reserve measurements from the DOCTORS (Does Optical Coherence Tomography Optimize Results of Stenting) study population. <i>Catheterization and Cardiovascular Interventions</i> , <b>2020</b> , 96, 1145-1153	2.7	12
104	Interleukin-1 $\beta$ and Risk of Premature Death in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 1763-1773	15.1	3
103	Reply: Left Ventricular Thrombus: When Registries Are Not Good Enough!. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 486-487	15.1	
102	Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008481	6	12
101	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1737-1744	40	28
100	Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e008296	6	5
99	Kidney in the transformation matrix. <i>European Heart Journal</i> , <b>2019</b> , 40, 1233-1235	9.5	2
98	Do Patients need Lifelong $\beta$ -Blockers after an Uncomplicated Myocardial Infarction?. <i>American Journal of Cardiovascular Drugs</i> , <b>2019</b> , 19, 431-438	4	5
97	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. <i>Drugs and Aging</i> , <b>2019</b> , 36, 531-539	4.7	9
96	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 906-914	15.1	9
95	On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 2260-2268	5	11
94	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007749	6	2
93	Long-Term Evolution of Premature Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1868-1878	15.1	26
92	Modulation of cholesterol efflux capacity in patients with myocardial infarction. <i>Current Opinion in Cardiology</i> , <b>2019</b> , 34, 714-720	2.1	1
91	Copeptin as a prognostic biomarker in acute myocardial infarction. <i>International Journal of Cardiology</i> , <b>2019</b> , 274, 337-341	3.2	14
90	Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 58-66	15.1	86
89	Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , <b>2019</b> , 112, 180-186	2.7	5
88	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , <b>2019</b> , 19, 173-183	4	15

87	Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. <i>International Journal of Cardiology</i> , <b>2018</b> , 254, 36-42	3.2	15
86	Periprocedural myocardial infarction and injury in elective coronary stenting. <i>European Heart Journal</i> , <b>2018</b> , 39, 1100-1109	9.5	82
85	Anticoagulation in Acute Coronary Syndrome-State of the Art. <i>Progress in Cardiovascular Diseases</i> , <b>2018</b> , 60, 508-513	8.5	12
84	Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 503-511	4	7
83	The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. <i>EuroIntervention</i> , <b>2018</b> , 14, 78-85	3.1	17
82	Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. <i>EuroIntervention</i> , <b>2018</b> , 14, 789-797	3.1	2
81	Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Heart</i> , <b>2018</b> , 104, 767-772	5.1	30
80	Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 3259-3269	15.1	36
79	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial. <i>Angiology</i> , <b>2017</b> , 68, 29-39	2.1	7
78	Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVEREST-HIV study. <i>European Heart Journal</i> , <b>2017</b> , 38, 1676-1686	9.5	16
77	Thrombus composition in sudden cardiac death from acute myocardial infarction. <i>Resuscitation</i> , <b>2017</b> , 113, 108-114	4	18
76	Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. <i>Circulation</i> , <b>2017</b> , 136, 1908-1919	16.7	191
75	One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study. <i>Journal of Invasive Cardiology</i> , <b>2017</b> , 29, 253-258	0.7	4
74	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet, The</i> , <b>2016</b> , 388, 2015-2022	40	217
73	Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting). <i>Circulation</i> , <b>2016</b> , 134, 906-17	16.7	148
72	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 369-78	7	83
71	Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 192-200	3.3	6
70	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-HII Analysis. <i>JACC: Cardiovascular Interventions</i> , <b>2016</b> , 9, 646-56	5	25

69	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2016</b> , 16, 43-53	4	2
68	Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 382-91	7	12
67	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians. <i>Heart</i> , <b>2016</b> , 102, 1648-54	5.1	11
66	Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1917-27	15.1	58
65	Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , <b>2015</b> , 108, 554-62	2.7	8
64	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , <b>2015</b> , 108, 502-10	2.7	6
63	Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , <b>2015</b> , 108, 428-36	2.7	11
62	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and	4.9	7
61	Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians: a multicenter study. <i>Journal of the American Geriatrics Society</i> , <b>2015</b> , 63, 384-6	5.6	1
60	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2015</b> , 1, 198-204	6.4	22
59	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1315-24	2.8	25
58	Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2015</b> , 4, 28-36	4.3	34
57	Assessment of the Anticoagulation Activity of Apixaban--Reply. <i>Circulation Journal</i> , <b>2015</b> , 79, 1642	2.9	
56	Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8, e002786	6	47
55	Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 10A-22A	3	17
54	One-year clinical outcomes of the STENTYS Self-Apposing□ coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. <i>EuroIntervention</i> , <b>2015</b> , 11, 264-71	3.1	23
53	High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. <i>Circulation</i> , <b>2014</b> , 129, 2136-43	16.7	36
52	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. <i>American Heart Journal</i> , <b>2014</b> , 168, 674-81	4.9	18

51	Prehospital ticagrelor in ST-segment elevation myocardial infarction. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1016-27	59.2	409
50	Coronary revascularization in the diabetic patient. <i>Circulation</i> , <b>2014</b> , 130, 918-22	16.7	15
49	Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 281-6	3.2	27
48	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1577-85	40	224
47	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 1049-57	2.8	9
46	Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1288-1294	15.1	54
45	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ, The</i> , <b>2014</b> , 349, g6269	5.9	62
44	Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. <i>Circulation</i> , <b>2014</b> , 130, 1904-14; discussion 1914	16.7	33
43	Reply: Do not miss the elephant in the room: look at the red blood cells. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2588-2589	15.1	
42	An evidence-based review of current anti-platelet options for STEMI patients. <i>International Journal of Cardiology</i> , <b>2013</b> , 166, 294-303	3.2	9
41	Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. <i>International Journal of Cardiology</i> , <b>2013</b> , 163, 266-271	3.2	19
40	Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 999-1010	59.2	424
39	A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). <i>American Journal of Cardiology</i> , <b>2013</b> , 112, 1367-72	3	40
38	Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 73-9	3.2	23
37	Switching acute coronary syndrome patients from prasugrel to clopidogrel. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 158-65	5	53
36	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , <b>2013</b> , 166, 100-106	4.9	39
35	Prasugrel monitoring and bleeding in real world patients. <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 38-44	3	37
34	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1055-64	7	9

33	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , <b>2012</b> , 79, 104-12	2.7	19
32	Premature coronary artery disease. <i>Sang Thrombose Vaisseaux</i> , <b>2012</b> , 24, 173-182	3	
31	Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2507-16	27.4	148
30	Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. <i>International Journal of Cardiology</i> , <b>2012</b> , 156, 69-75	3.2	32
29	Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry. <i>Archives of Cardiovascular Diseases</i> , <b>2012</b> , 105, 347-54	2.7	10
28	Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty. <i>Archives of Cardiovascular Diseases</i> , <b>2012</b> , 105, 639-48	2.7	13
27	Bedside monitoring to adjust antiplatelet therapy for coronary stenting. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 2100-9	59.2	637
26	Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study. <i>Catheterization and Cardiovascular Interventions</i> , <b>2012</b> , 79, 823-33	2.7	9
25	Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2012</b> , 344, e553	5.9	124
24	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , <b>2012</b> , 33, 1241-9	9.5	107
23	Pharmacogenetics of clopidogrel. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5309-27	3.3	10
22	Composition of coronary thrombus in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 1359-67	15.1	266
21	One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. <i>Archives of Cardiovascular Diseases</i> , <b>2011</b> , 104, 604-10	2.7	11
20	Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <i>Lancet, The</i> , <b>2011</b> , 378, 693-703	4.0	217
19	FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype-phenotype case control study. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 511-20	7	11
18	Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER study. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 105, 1024-31	7	4
17	CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 422-8	6	98
16	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , <b>2011</b> , 77, 182-90	2.7	26

15	High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 392-402	5	98
14	Antiplatelet options for secondary prevention in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2011</b> , 9, 1403-15	2.5	1
13	Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1765-74	27.4	150
12	Optimal use of thienopyridines in non-ST-elevation acute coronary syndrome following CURRENT-OASIS 7. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 95-103	6	12
11	Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 617-25	15.1	20
10	Slow response to clopidogrel predicts low response. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 815-22	15.1	22
9	Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 134-43	15.1	311
8	New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1542-51	15.1	86
7	Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. <i>European Heart Journal</i> , <b>2010</b> , 31, 2816-21	9.5	52
6	Usefulness of biomarker strategy to improve GRACE score prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 650-8	3	26
5	Oral Antiplatelet Therapy <b>2010</b> , 73-82		
4	Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 947-54	27.4	195
3	Can we override clopidogrel resistance?. <i>Circulation</i> , <b>2009</b> , 119, 2854-7	16.7	95
2	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet, The</i> , <b>2009</b> , 373, 309-17	40	755
1	Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. <i>Circulation</i> , <b>2008</b> , 118, 1225-33	16.7	73